Building a Better Drug for Schizophrenia
This article was originally published in Start Up
Executive Summary
Start-ups in pursuit of novel targets are capturing the attention of venture capitalists.
You may also be interested in...
Potomac Pharmaceuticals Inc.
Off-label use of multiple drugs has become a widespread clinical practice in treating schizophrenia. Potomac Pharma Inc. aims to improve outcomes by developing a highly selective alpha-2 antagonists for adjunctive use in treating neurological and psychiatric disorders.
Xytis Pharmaceuticals Ltd.
Xytis Pharmaceuticals Ltd., focused on in-licensing and developing late-stage CNS drug candidates, is taking a unique approach to treating schizophrenia by developing a drug that targets the NMDA receptor complex.
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is developing treatments for schizophrenia by rescuing previously discontinued compounds and developing them into individualized therapeutics through the use of pharmacogenomics and pharmacogenetics.